Avid Bioservices Inc (CDMO)

[jakedogman1]

For what? Poor mgmt decisions... and the travails of biotech?

Look at the pathway IDO1 ... a year ago it was the next best thing ....Incyte was in the catbird seat.... in a year over $13 bil market cap erased...

https://www.fiercebiotech.com/biotech/incyte-climbs-combo-data-for-ido-inhibitor-epacadostat

https://www.fiercebiotech.com/biotech/body-blow-for-incyte-as-merck-partnered-melanoma-trial-bombs


Note the latter part of the article...

Analysts at Bernstein said in a note to clients: "The failure of IDO adds to the list of disappointment with "second generation" IO drugs – promises by companies and KOLs that the industry was just scratching the surface with anti-PDx therapies have not come true, at least yet. This means that for now, PDx monotherapy, PDx+chemotherapy, and PDx+CTLA4 may end up continuing to be the dominant regimens (evidence in support of the latter continues to build)."

also note the new Oncologie website mentions Head and Neck trial which was phase 2 with Keytruda... doubt they would put that up without an update... and planned trials in Asia? With biomarker data? the IP is not dead but CDMO will only get a pieces of value as it moves forward... Ronin made the right call in getting CDMO going... they could not have pulled off trials and avid biz... any IP value will be gravy...